Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in ASCVD (PREVAIL)
NCT05202509Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Feb 2022
- Primary completion
- Nov 2026
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing Obicetrapib 10mg with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 30 months. Started Feb 2022; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05202509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202509.